Business, energy, technology, markets and global industry news from Business News Today

Alcon

Medical Devices & Diagnostics

Why Alcon and Aravind’s 60-trainee retina surgery hub could matter far beyond Coimbatore

Aravind Eye Care System and Alcon open a Coimbatore retina training hub aimed at expanding vitreoretinal surgical expertise worldwide.

Read More
Medical Devices & Diagnostics

i-Lumen Scientific begins U.S. pivotal trial of microcurrent therapy for dry AMD

i-Lumen Scientific, Inc. has randomized the first United States patient in its pivotal i-SIGHT2 study, beginning the domestic phase of a multinational trial evaluating whether low-level electrical stimulation delivered through a closed eyelid can improve visual function in people with intermediate-to-advanced dry age-related macular degeneration. The first U.S. randomization occurred at Texas Retina Associates in

Read More
Medical Devices & Diagnostics

Alcon is paying RxSight $60m upfront to make premium cataract lenses adjustable after surgery

Alcon and RxSight will develop adjustable presbyopia-correcting intraocular lenses that could allow surgeons to refine vision after cataract surgery, although the programme still faces clinical, regulatory and workflow risks.

Read More
Pharma & Biotech

Can Alcon turn baseball fandom into a growth engine for Systane in Canada’s dry eye category?

See how Alcon is using the Toronto Blue Jays to expand Systane’s dry eye reach in Canada and what it means for eye care competition.

Read More
Medical Devices & Diagnostics

Is Alcon redefining the enhanced monofocal category with Clareon TruPlus at ASCRS 2026?

Alcon launched Clareon TruPlus at ASCRS 2026. Read why the new enhanced monofocal IOL could reshape cataract lens choice.

Read More
Medical Devices & Diagnostics

Why Alcon’s TOTAL30 Multifocal for Astigmatism targets the toughest segment in contact lens care

Alcon has launched TOTAL30 Multifocal for Astigmatism in the U.S. Find out why this matters for presbyopia care and contact lens adoption.

Read More